Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Hana Biosciences is a development stage biopharmaceutical company focused on the acquisition, development and commercialisation of innovative products to enhance cancer care. Hana aims to acquire proprietary rights to these products, by licence or otherwise, fund their research and development and bring the products to market.

Hana's objective is to be a leading oncology company. Its business model focuses on leveraging its experienced biopharmaceutical management team to advance its unique product candidates through translational research for timely transfer from the lab to clinical trials. Hana believes risk is mitigated by targeting multiple technologies with well-validated mechanisms of action and strong intellectual property rights to set the platform for accelerated growth.